Real-world clinical and economic outcomes in patients with type 2 diabetes initiating glargine disposable pen vs. insulin detemir disposable pen in a US managed care setting

Trial Profile

Real-world clinical and economic outcomes in patients with type 2 diabetes initiating glargine disposable pen vs. insulin detemir disposable pen in a US managed care setting

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jun 2014

At a glance

  • Drugs Insulin detemir; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Sep 2011 New trial record
    • 16 Sep 2011 Results presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top